Colleges
Udo Oppermann
Professor of Molecular Biology
- Director of Molecular Laboratory Sciences, Botnar Research Centre
- Deputy Director Oxford Centre of Translational Myeloma Research
Professor Udo Oppermann obtained his Diploma in Human Biology in 1990 and his PhD in Pharmacology and Toxicology in 1994, both with distinctions from Philipps University Marburg, Germany.
He went on to become Associate Professor at Karolinska Institutet, Stockholm, in the Department of Medical Biochemistry and Biophysics where he stayed until 2004.
After a sabbatical stay at Yale University, he has been a Principal Investigator of the Structural Genomics Consortium (SGC) in Oxford since its inception in 2003.
In 2008 he became Professor of Molecular Biology at NDORMS, and he is now Director of the Laboratory Sciences Division at the Institute of Musculoskeletal Sciences, Botnar Research Centre, University of Oxford. He is a fellow of St Catherine's College at Oxford University as well as an alumnus of the Freiburg Institute of Advanced Studies through a Senior Marie Curie fellowship.
The research in the Oppermann group focuses on drug and target discovery by using systems biology and single-cell approaches in a variety of human diseases including metabolic, inflammatory and malignant diseases. Application of novel single-cell technologies and chemical biology in primary and secondary bone cancers such as multiple myeloma with a focus on epigenetic mechanisms is a key research area of the group.
Funding
- Cancer Research UK
- Innovate UK
- EPSRC
- Royal Society- Newton Fund
- Bristol Myers Squibb
- Bayer Healthcare
- GlaxoSmithKline
- Blood Cancer UK
- Leducq Foundation
Key publications
-
Histone H3K27me3 demethylases regulate human Th17 cell development and effector functions by impacting on metabolism.
Journal article
Cribbs AP. et al, (2020), Proc natl acad sci u s a, 117, 6056 - 6066
-
Bromodomain inhibition of the coactivators CBP/EP300 facilitate cellular reprogramming.
Journal article
Ebrahimi A. et al, (2019), Nat chem biol, 15, 519 - 528
-
A Chemical Probe for Tudor Domain Protein Spindlin1 to Investigate Chromatin Function.
Journal article
Fagan V. et al, (2019), J med chem, 62, 9008 - 9025
-
Structural analysis of human KDM5B guides histone demethylase inhibitor development.
Journal article
Johansson C. et al, (2016), Nat chem biol, 12, 539 - 545
-
A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response.
Journal article
Kruidenier L. et al, (2012), Nature, 488, 404 - 408
-
Crystal structures of histone demethylase JMJD2A reveal basis for substrate specificity.
Journal article
Ng SS. et al, (2007), Nature, 448, 87 - 91
Recent publications
-
Investigation of the mechanisms of sonodynamic therapy
Thesis / Dissertation
Singh K. and Oppermann U., (2024)
-
Determinants of durable humoral and T cell immunity in myeloma patients following COVID-19 vaccination.
Journal article
Twumasi C. et al, (2023), Eur j haematol
-
KMT2A associates with PHF5A-PHF14-HMG20A-RAI1 subcomplex in pancreatic cancer stem cells and epigenetically regulates their characteristics.
Journal article
Mouti MA. et al, (2023), Nat commun, 14
-
Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma.
Journal article
Kurata K. et al, (2023), Blood cancer j, 13
-
Long-Read Single-Cell Sequencing Using scCOLOR-seq.
Journal article
Philpott M. et al, (2023), Methods mol biol, 2632, 259 - 267
-
Recognition of Dimethylarginine Analogues by Tandem Tudor Domain Protein Spindlin1
Journal article
Porzberg MRB. et al, (2022), Molecules, 27, 983 - 983